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Abstract
This article exemplifies a systematic approach to revealing the complexity of Chinese herbal
medicine formulae through three levels of scientific research: standardization of herbs, verification
of ancient formulae and mechanism studies. We use Danggui Buxue Tang (DBT) as an example for
this approach. Among thousands of traditional Chinese medicine herbal formulae, almost all of
which consist of multiple herbs, DBT is one of the simplest. Containing only two herbs, namely Radix
Astragali (RA) and Radix Angelicae Sinensis (RAS), DBT is traditionally used to treat ailments in women.
The weight ratio of RA to RAS in DBT was prescribed to be 5:1 as early as in 1247 AD. In addition
to advanced chemical analysis of herbal constituents, DNA genotyping techniques have been
developed for reliable standardization of RA and RAS. Chemical evaluation shows that main active
constituents in DBT, including astragaloside IV, calycosin, formononetin and ferulic acid, were most
abundant after extraction at the RA to RAS ratio of 5:1, whereas other tested RA to RAS ratios only
gave sub-optimal levels of the active constituents. Biological evaluation indicates that bioactivities
of DBT, e.g. immuno-modulatory, oesteotropic and estrogenic effects are also best exerted at the
RA  to  RAS  ratio of 5:1. Correlation analysis demonstrates statistically significant relationship
between the tested chemical constituents and tested bioactivities. Up- and down-regulation of
expression of some genes as potential biomarkers has been detected by using gene chip technology.
This systematic approach on the basis of herbal standardization, chemical and biological verification
and mechanism studies, as exemplified in this article, will be useful to reveal the complexity of not
only DBT but also other Chinese medicine herbal formulae.
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Background
Traditional Chinese medicine (TCM) has been used to
improve the well-being of the Chinese people for thou-
sands of years. TCM products, many of which were raw
materials, made up only 3% of the 16 billion USD inter-
national herbal medicine market in 2004 [1,2]. Since the
market opening-up of China, international pharmaceuti-
cal companies have been gaining a market share in both
conventional and herbal medicine products in China. In
the 21st century, TCM products should meet stringent
international quality and safety standards through mod-
ernization; otherwise they will lose their competitiveness.
Standardization as the basis of modernization and inter-
nationalization of TCM is the key to ensure the safety and
efficacy of TCM products. At present, lack of standardiza-
tion in TCM products impedes the development of TCM.
For instance, it is common that different herbs have the
same name or a single herb has different names in the
market. Some herbs cultivated in different regions or har-
vested in different seasons may vary considerably in their
chemical and biological properties. Most of the TCM
products do not have specific biomarkers. TCM is tradi-
tionally administered in the form of a decoction with a
combination of different herbs. The complexity of biolog-
ical effects of the interactions among different com-
pounds within a decoction complicates experimental
studies to reveal the action mechanisms.
Among thousands of TCM formulae, Danggui Buxue Tang
(DBT) is one of the simplest. The formula consists of only
two herbs: Radix Astragali (RA, Huangqi) and Radix Angel-
icae Sinensis (RAS, Danggui) in a weight ratio of 5:1.
According to a traditional method, the herbs are boiled
together in two bowls of water at moderate heat until the
final volume has been reduced to one bowl [2]. In a book
entitled Neiwaishang Bianhuo Lun in 1247 AD, DBT was
first described by Li Dongyuan, one of the four well-
known TCM physicians during the Jin and Yuan Dynasties
in China.
In this review, we summarize recent findings of DBT to
exemplify a systematic approach to revealing the complex-
ity of Chinese herbal medicine formulae through three
levels of scientific research: standardization of raw materi-
als, verification of ancient formulae and mechanism stud-
ies.
Standardization of Radix Astragali and Radix Angelicae 
Sinensis
A reliably reproducible chemical composition of DBT is a
prerequisite in delineating the biological effects of this
Chinese medicine preparation. The quality of RA and RAS
may be considerably influenced by weather, geographic
location, soil conditions, and the methods of cultivation
and processing. Some Chinese medicinal materials with
excellent quality are only produced in certain regions of
China which are often referred to as 'the best growth
region' or 'Didao'. Therefore, how to authenticate and
choose the best RA and RAS plays a critical role in ensur-
ing the quality of DBT (Figure 1).
Radix Astragali
Astragalus  L. (Leguminosae) is a large genus with over
2,000 species worldwide and more than 250 sections in
angiosperm family Fabaceae  (subfamily  Papilionoideae).
Both listed as the botanical sources of RA in Chinese Phar-
macopoeia (2005) [3], Astragalus membranaceus (Fisch.)
Bunge and Astragalus membranaceus (Fisch.) Bunge var.
mongholicus (Bunge) P.K. Hsiao [4,5] are the most com-
monly used RA. The morphological appearances and
chemical properties of RA  and its adulterants show a
remarkable resemblance [6-8]. The DNA sequences of 5S
rRNA spacer, ITS and 18S rRNA coding region were deter-
mined and compared among ten Astragalus  taxa [6-8].
With neighbor-joining and maximum parsimony analy-
ses, phylogenetic trees were mapped according to their
sequence diversity. A. membranaceus and A. membranaceus
var.mongholicus have the highest sequence homology. The
common substitute of RA in some parts of China is the
roots of Hedysarum polybotrys which has very different
The authentic sources of RA and RAS Figure 1
The authentic sources of RA and RAS. (a) A. mem-
branaceus and (b) A. membranaceus var. mongholicus are the 
sources for RA. (c) H polybotrys is a common substitute for 
RA. (d) A. sinensis is the source for RAS. (e) A. acutiloba and 
(f) A. gigas are also sold as raw materials for RAS in the mar-
kets.
(a) A. membranaceus (b) A. membranaceus 
var. mongholicus
(c) H. polybotrys
(d) A. sinensis (e) A. acutiloba (f) A. gigasChinese Medicine 2007, 2:12 http://www.cmjournal.org/content/2/1/12
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genetic makeup from that of the Astragalus  species [9]
(Figure 1).
HPLC and spectrophotometry were used to determine the
levels of isoflavonoids, astragalosides, polysaccharides,
amino acids and trace elements, which are the main active
constituents in different Astragalus  species and RA  col-
lected in different seasons and of various ages. The results
indicated that RA of three years of age from Shanxi, China
(Figure 2a) contained the highest amounts of isoflavo-
noids, saponins and polysaccharides [6,10].
Radix Angelicae Sinensis
According to the Chinese Pharmacopoeia (2005) [3], RAS
is the root of Angelica sinensis (Oliv.) Diels (family Umbel-
laceae); however, Angelica acutiloba (Sieb. et Zucc.) Kitag.
Determination of the active constituents in RA and RAS Figure 2
Determination of the active constituents in RA and RAS. (a) Amounts of total saponin, total isoflavonoid and total 
polysaccharides were determined in RA collected from various regions in China. (b) Amounts of ferulic acid and ligustilide 
were determined in RAS collected from various regions and countries. The roots of A. sinensis collected from Gansu, Yunnan, 
Sichuan and Shanxi, China were used. The roots of A. acutiloba from Hokkaido, Japan and A. gigas from Sokcho, Korea were 
used. Values are in g/100 g of dry herbal materials with means ± SEM, n = 10. (c) RAS from Gansu, China and RA from Shanxi, 
China should be used for DBT preparation.Chinese Medicine 2007, 2:12 http://www.cmjournal.org/content/2/1/12
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and  Angelica gigas Nakai, mainly found in Japan and
Korea respectively, are also sold as RAS in the markets of
South East Asia [11-14] (Figure 1). Studies have shown
that the three commonly used Angelica roots vary in their
chemical composition, pharmacological properties and
efficacy [9,11]. The 5S-rRNA spacer domains of the three
species of Angelica were amplified and their nucleotide
sequences were determined. The sequence of A. sinensis is
72.87% and 73.58% identical to those of A. acutiloba and
A. gigas respectively, while A. acutiloba and A. gigas are
93.57% identical in their sequences [9]. The phylogenetic
tree clearly reveals that the three Angelica  species are
divided into two clusters: A. sinensis is in one cluster and
A. acutiloba and A. gigas are in another.
The main chemical constituents of Angelica roots are feru-
lic acid, Z-ligustilide, angelicide, brefeldin A, butyli-
denephthalide, butyphthalide, succinic acid, nicotinic
acid, uracil and adenine [9,15-17]. The levels of ferulic
acid and Z-ligustilide are often used as chemical markers
for the quality control of Angelica roots [16]. In A. sinensis
roots from Gansu, China, the levels of ferulic acid and Z-
ligustilide are about ten-fold higher than those of the
roots of A. acutiloba (from Japan) and A. gigas (from
Korea) [9,17] (Figure 2b). Su Jing (659 AD) in Tang Ben-
cao and Li Shizhen (1596 AD) in Bencao Gangmu recorded
that Angelica roots of two years of age produced in Gansu
were the authentic source. RAS  from Gansu contains
about two-fold higher amounts of Z-ligustilide and ferulic
acid than those RAS from Yunnan, Shanxi or Sichuan,
China [9] (Figure 2b). To ensure the best quality of DBT
decoction, we suggest that standardized RA from Shanxi
and standardized RAS from Gansu should be used in all
DBT preparations (Figure 2c).
Verification of the DBT formula
Chemical evaluation
Li Dongyuan (1247 AD) documented that RA and RAS
combined at a ratio of 5:1 demonstrated the best efficacy.
In a previous study [18], DBT was prepared by boiling the
herbal mixture under various conditions and the results
indicated that the 5:1 ratio indeed provided the maximum
levels of active constituents of DBT. Furthermore, the lev-
els of active constituents and biological activities of DBT
extracts were investigated with preparations of RA and
RAS at ratios of 1:1, 2:1, 3:1, 4:1, 5:1, 7:1 and 10:1.
Used as chemical markers, the main active constituents in
DBT include RA-derived astragaloside IV, calycosin and
formononetin,  RAS-derived ferulic acid and ligustilide,
and total saponins, total flavonoids and total polysaccha-
rides [19]. The detected levels of the chemical markers var-
ied significantly among the seven preparations (Figure 3).
The level of astragaloside IV of the 5:1 ratio preparation
was the highest, 2-fold higher than the 10:1 ratio prepara-
tion which recorded the lowest level [19]. The 5:1 ratio
preparation also contained the highest level of calycosin,
formononetin, and ferulic acid. As regards the levels of
total saponins, total flavonoids and total polysaccharides,
the 5:1 ratio DBT preparation recorded the highest levels
(Figure 3) [19].
There are several possibilities for higher levels of active
chemical constituents in DBT preparations. Firstly, com-
pounds such as saponins (over 2% in total dry weight)
[10,17] in RA may help increase the solubility of other
compounds extracted from RAS. For example, astragalo-
side increases the solubility of RAS-derived ferulic acid
and ligustilide. Secondly, ferulic acid and ligustilide are
readily oxidized under heat, which means they can be
degraded when boiled [9]. However, when RAS is boiled
together with RA, compounds derived from RA may pre-
vent this oxidization process, thereby producing a higher
yield of ferulic acid and ligustilide in DBT preparations.
Thirdly, the stability of those active constituents may be
improved by having a cocktail of different chemicals. Fur-
ther research is required for better understanding of this
complexity.
Biological evaluation
According to TCM theories, DBT replenishes qi and nour-
ishes xue (the blood). DBT is therefore used for treating
menopausal symptoms [2]. Due to a deficiency of ovarian
hormones, especially estrogen, women in menopause
often suffer from hot flashes, sweating, anxiety, mood
swings and an increased risk for other health problems,
such as reduction of bone mineral density and cardiovas-
cular diseases [20]. Apart from a lack of estrogen, the
immune system is also involved in the menopausal symp-
toms. Steroid hormones may modulate the immune
response [21] and immune reactions may also regulate
the ovarian function [22]. Various bioactivities related to
menopausal symptoms, such as osteotropic effect, estro-
genic effect, anti-platelet aggregation effect and immuno-
modulatory effect have been used to evaluate the func-
tional roles of DBT.
DBT extract was applied to a cultured human MG-63 oste-
osarcoma cell. Bone cell proliferation and differentiation
were measured by 3-(4, 5-dimethylthioazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) assay and alkaline
phosphatase (ALP) assay. DBT induced both the prolifer-
ation and differentiation of osteoblast MG-63 cells in a
dose-dependent manner. In both assays, DBT  showed
stronger effects than RA or RAS alone, In the MTT assay,
the 5:1 ratio DBT extract stimulated MG-63 cell prolifera-
tion, which was 10–20% higher than the extracts of other
ratios (Figure 4). For bone cell differentiation, the 5:1
ratio DBT preparation induced ALP activity to the highestChinese Medicine 2007, 2:12 http://www.cmjournal.org/content/2/1/12
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level among all ratios and showed the strongest osteo-
tropic effect [19].
The estrogenic effects of DBT  were tested by a cellular
reporter system of transcriptional activation of estrogen
receptor/promoter. A promoter/reporter construct (pERE-
Luc) corresponding to the responsive elements of estro-
gen receptor was stably transfected into MCF-7 cells. The
DBT extracts of various ratios were applied onto the cul-
tures for 2 days. Two parameters, namely cell number and
promoter activity (luciferase activity), were determined.
While DBT was not able to alter the proliferation of MCF-
7 cells, the estrogen-driven promoter activity was mark-
edly induced by DBT (Figure 4); the 5:1 ratio DBT showed
the strongest effect in inducing the promoter activity than
RA, RAS alone or the extracts of other ratios [19].
In anti-platelet aggregation assay, the activity of DBT in
preventing ADP-induced platelet aggregation was deter-
mined. The ratios 5:1 and 7:1 DBT extracts demonstrated
higher levels of activity in preventing platelet aggregation
than either RA, RAS alone or the extracts of other ratios
(Figure 4) [19].
In a study of immuno-modulatory effects, DBT prepara-
tions of various ratios were applied to cultured T-lym-
phocytes and macrophages. In cultured T-lymphocytes,
DBT  induced markedly cell proliferation, interleukin-2
secretion and the phosphorylation of extracellular signal-
regulated kinase (ERK1/2). In addition, the phagocytosis
of cultured macrophages was elevated by DBT treatment.
The immuno-modulatory effects of 5:1 ratio DBT were the
strongest [23] (Table 1).
In addition to the in vitro assays, the 5:1 ratio of RA and
RAS  in DBT  was further tested and verified by animal
studies. In DBT-administrated mice, the 5:1 ratio prepara-
tion was the most effective decoction in triggering
immune responses [24,25].
The pharmacological studies in animals also suggest that
DBT has the ability to promote hematopoiesis, to stimu-
late blood circulation, to prevent osteoporosis and to
counter oxidative stress [19,26,27]. Moreover, DBT  is
known to enhance myocardial mitochondria and glutath-
ione status in red blood cells, thereby increasing their
resistance to injury induced by oxidative stress [28]. In
Chemical constituents in RA, RAS and DBT Figure 3
Chemical constituents in RA, RAS and DBT. (a) The amounts of astragaloside IV, calycosin, formononetin in DBT of vari-
ous ratios of RA to RAS. (b) The amounts of Ligustilide, ferulic acid and total polysaccharides in DBT of various ratios of RA to 
RAS. Values are in mg/g of dry material (normalized by each herb weight) with means ± SEM, n = 5, each with triplicate samples.Chinese Medicine 2007, 2:12 http://www.cmjournal.org/content/2/1/12
Page 6 of 10
(page number not for citation purposes)
rats,  DBT  protected against myocardial ischemia-reper-
fusion injury in a dose-dependent manner [28]. A more
potent cardio-protection was demonstrated in DBT-
treated rats than in rats treated with either extracts of RA,
RAS  alone, or a mixture of RA  and  RAS  (not boiled
together). When the mice were administered orally with
DBT, the serum collected from abdominal aorta was
added to an in vitro cultivating system of mouse hemat-
opoietic progenitor cells. The decoction-contained serum
showed promoting actions to CFU-GM and CFU-E. Once
again, the action of the 5:1 ratio DBT was 97.81% stronger
than that of the 1:1 ratio extract [29,30] (Table 2).
Mechanism studies
Correlation between chemical fingerprints and bioactivities of DBT
Fifty-four chemical peaks were detected in DBT extracts by
an HPLC analysis (Figure 5a) and a total of over 100 DBT
extracts from various preparations were analyzed [27].
Among these 54 peaks, the markers for RA-derived astra-
galoside IV, calycosin and formononetin, and for RAS-
derived ferulic acid and ligustilide were identified. In anal-
ysis of correlation, the identified 54 peak areas together
with the contents of total saponins, total flavonoids and
total polysaccharides were considered as independent var-
iables. The results of the four bioactivities, namely prolif-
eration and differentiation of MG-63 cells, estrogenic
property in MCF-7 cells and anti-platelet aggregation
activity, were considered as dependent variables. By ana-
lyzing the correlation of these two kinds of variables, coef-
ficients of correlation between the HPLC data of the 57
chemicals and the bioassay data of the DBT extracts were
obtained. The values of the coefficients indicate possible
relationship of these chemical peaks with bioactivities,
where positive values suggest positive effects of chemicals
Table 1: Biological evaluation of DBT (in vitro studies)
Findings Model Treatment Reference
The 5:1 ratio DBT showed stronger effects in 
stimulating MG-63 cell proliferation and induced 
ALP activity to the highest level among all 
groups.
Cultured human MG-63 
osteosarcoma cells
DBT of various ratios of RA and RAS, 
compared with β-estradiol and negative 
control
Dong et al. [19]
The 5:1 ratio DBT showed the strongest effect in 
inducing the estrogen-driven promoter activity 
than RA, RAS alone or the extracts of other 
ratios.
Cultured MCF-7 cells DBT of various ratios of RA and RAS, 
compared with β-estradiol and negative 
control
Dong et al. [19]
The ratios 5:1 and 7:1 DBT showed higher levels 
of activity in preventing platelet aggregation.
ADP induced-platelet aggregation 
in blood from adult New Zealand 
white rabbits
DBT of various ratios of RA and RAS, 
compared with ticlopidine and negative 
control
Dong et al. [19]
DBT induced cell proliferation, interleukin-2 
secretion and the phosphorylation of 
extracellular signal-regulated kinase (ERK1/2) in 
cultured T-lymphocytes. The 5:1 ratio DBT 
showed the strongest immuno-modulatory 
effects.
Cultured T-lymphocytes and 
macrophages
DBT of various ratios of RA and RAS, 
compared with PHA, PMA, Zymosan A 
and negative control
Gao et al. [23]
Biological activities of RA, RAS and DBT of various RA to RAS  ratios Figure 4
Biological activities of RA, RAS and DBT of various RA 
to RAS ratios. RA, RAS and DBT of various RA to RAS ratios 
were tested for MG-63 cell proliferation (MTT assay), MG-
63 cell differentiation (ALP assay), estrogenic response 
(estrogen promoter) and anti-platelet aggregation activity. 
The values are means ± SD, n = 5, each with triplicate sam-
ples.Chinese Medicine 2007, 2:12 http://www.cmjournal.org/content/2/1/12
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on bioactivities and negative values suggest negative
effects.
In the assay of MG-63 cell proliferation, astragaloside IV,
formononetin, total saponins and total flavonoids are
correlated with the bioactivities (Figure 5b). In the assay
of MG-63 cell differentiation, formononetin, total sapon-
ins and total flavonoids are correlated with the bioactivi-
ties. In the analysis of estrogen promoter in MCF-7 cells,
ferulic acid are correlated with the bioactivities. Calycosin
and total polysaccharides were two very important factors
in the assay of anti-platelet aggregation. On the other
hand, the amount of ligustilide showed negative effects in
all bioassays (Figure 5b). Other components of DBT, such
as those corresponding to peaks 5 to 15, have high corre-
lation coefficients with the bioactivities, but are yet to be
identified.
Specific estrogenic and immuno-modulatory effects of DBT
The estrogenic effects of DBT were investigated by deter-
mining the levels of phosphorylation of estrogen receptor
α (ERα) and extracellular signal-regulated kinase 1/2
(ERK1/2) in cultured MCF-7 cells. In contrast to estrogen,
DBT triggered the phosphorylation of ERα and ERK1/2 at
both S118 and S167 in a time-dependent manner.
Although the activity of the estrogen-responsive element
in pERE-Luc stably expressing MCF-7 cells was activated
by extracts of either RA or RAS alone, or by a mixture of
RA and RAS, the phosphorylation of ERα at S167 and of
ERK1/2 were only found in DBT-treated cultures. Interest-
ingly, the specific estrogenic effects of DBT were not only
shown in the MCF-7 cells [31].
In cultured T-lymphocytes, the phosphorylation of the
ERK 1 (about 42 kDa) and ERK 2 (about 44 kDa) was
increased by DBT [30]. The induction was transient. An
approximately eight-fold increase of ERK phosphoryla-
tion was detected 20 minutes after DBT  was applied,
whereas the phosphorylation was undetectable in the cul-
tures treated with extracts of either RA or RAS alone [31].
Moreover, the phosphorylation of ERK in T-lymphocytes
could not be activated by a simple mixture of extracts of
RA and RAS. This result suggests that boiling RA and RAS
together is essential for DBT to exert estrogenic effects.
Genomics
For decades, scientists mainly isolated pure chemicals
from herbal extracts and then screened for biological
activities and possible targets. This strategy does not
garantee to isolate and/or identify active chemicals from
well-known medicinal plants because a single chemical
compound may not fully account for the overall effects of
herbal extracts. Recent advances in genomics and pro-
teomics have enriched our tool sets to reveal the complex
nature of TCM decoctions. An experiment on DBT-regu-
lated genes was carried out in our laboratory using gene
Table 2: Biological evaluation of DBT (in vivo studies)
Findings Model Treatment Reference
DBT had significantly higher RBC and Hb 
levels in both normal and anemic mice 
than those in RA, RAS and control.
Kunming mice, male, RBC, Hb Normal mice in 4 groups: RA, RAS, DBT 
and control; Anemic mice in 4 groups: RA, 
RAS, DBT and control
Wu BC et al. [24]
DBT was the most effective decoction in 
triggering immune responses.
Kunming mice, RBC, Hb, WBC, Plt, 
reticulocyte, nucleated cells of bone 
cavity, weight of pancreas and 
thymus
Mice in 5 groups: RA, RAS, DBT, RA+RAS 
(1:1) and control
Li YK et al. [25]
DBT alleviated cardiac injury in ischemia 
reperfusion.
Wister rats (male), amplitudes of 
LVSP and ± dp/dtmax, arterial 
pressure, Na+-K+-ATP activity, level 
of MDA production, cAMP content
Rats in myocardial ischemia reperfusion 
injury; i.v.
Wu DZ et al. [26]
DBT increased the levels of RBC, WBC, 
and BMNC. Some DBT promoted the 
proliferation of BMNC and increased the 
level of CFU-Mix.
Kunming mice, ICR mice, Balb/c 
mice, RBC, WBC, reticulocytes and 
BMNC
Mice in 4 groups: normal, model, DBT 
without polysaccharides, DBT with 
polysaccharides
Ning L et al. [27]
DBT enhanced myocardial mitochondria 
and red blood cell glutathione status.
Rats, myocardial mitochondrial 
status, RBC glutathione status
Rats in 5 groups: RA, RAS, DBT, RA + RAS 
(not boiled together) and control; orally 
administered
Mak DH et al. [28]
DBT inhibited growth of GM-CFU, while 
the decoction-containing serum 
promoted growth of GM-CFU.
Kunming mice, GM-CFU DBT was administered orally; serum 
collected from abdominal aorta was 
added to an in vitro cultivating system of 
mouse hematopoietic progenitor cells.
Zhang YH et al. [29]
The decoction-containing serum showed 
promoting actions to CFU-E. RA+RAS 
(5:1) was 97.81% stronger than RA+RAS 
(1:1).
Kunming mice, CFU-E DBT was administered orally; serum 
collected from abdominal aorta was 
added to an in vitro cultivating system of 
mouse hematopoietic progenitor cells.
Zhang YH et al. [30]Chinese Medicine 2007, 2:12 http://www.cmjournal.org/content/2/1/12
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Correlation coefficients between the data of 57 chemicals and the four bioassays Figure 5
Correlation coefficients between the data of 57 chemicals and the four bioassays. (a) Fifty-four peaks in typical 
HPLC fingerprints of DBT. In the HPLC fingerprint of 203 nm, astragaloside IV and other 16 peaks had a retention time 
between 70 to 120 min. In the HPLC fingerprint of 254 nm, ferulic acid, calycosin, formononetin, ligustilide and other 32 peaks 
had a retention time between 0 to 70 min. The 54 peaks are numbered, where astragaloside IV (1), ferulic acid (19), calycosin 
(33), formononetin (50) and ligustilide (53) are identified and served as standards. (b) The correlation coefficients between the 
data of 57 chemicals with the four bioassays. The correlation coefficient is in Y-axis and the peak number is in X-axis. Individual 
chemical markers are indicated by arrowheads and denoted by astragaloside IV (A), ferulic acid (B), calycosin (C), formonone-
tin (D), ligustilide (E), total saponins (F), total flavonoids (G) and total polysaccharides (H). All correlations were tested to be 
statistically significant (P < 0.05).
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chip (i.e. microarray) technology. Cultured MG-63 cells
were treated with 1 mg/ml of RA, RAS  or DBT  for 24
hours. The isolated mRNAs were analyzed using microar-
ray, which is a quantitative method to investigate the
change of mRNA expression profiles between the control
and treatment groups. A total of 8064 genes were
screened. Significant changes in gene expression were
found after the treatment of DBT, RA or RAS (Table 3). A
total of 883 genes were either up or down regulated by
DBT treatment of which 403 genes were DBT-specific; 660
genes were regulated by RA treatment of which 172 genes
were RA-specific; 1,062 genes were regulated by RAS treat-
ment of which 473 genes were RAS-specific. In addition,
279 genes were commonly regulated by the extracts of
DBT, RA or RAS. The genomic analysis demonstrated not
only the activation effect of DBT in stimulating the prolif-
eration and differentiation of the cultured osteoblasts but
also a set of candidates of biomarkers that are specifically
activated by DBT. These DBT-specific changes in gene
expression may be useful in developing biomarkers for
quality control of DBT. After identification of these DBT-
specific genes and their roles, it will be easier to elucidate
the action mechanism of DBT.
Conclusion
In verification studies of DBT decoction, the quality of
herbal materials is ensured by authentication analysis.
The ancient formula of RA to RAS ratio at 5:1 has been
confirmed in both chemical composition and biological
responses both in vivo and in vitro. Mechanism studies
have also revealed some therapeutic effects of DBT. It is
hoped that a systematic research and development
approach, as exemplified in this article, will provide an
effective method to develop Chinese herbal medicine
products.
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